ABVX
Abivax SA
NASDAQ · Healthcare · Biotechnology · FR
$89.16
+0.51%Forward multiples
Based on analyst estimates
- P/E forward
- —
- P/E 2026E
- —
- P/E 2027E
- —
- P/E 2028E
- —
- P/S forward
- 5907.95x
Trailing multiples
Trailing twelve months
- P/E TTM
- —
- PEG TTM
- —
- Price / book
- 19.06x
- Price / sales
- —
- Price / cash flow
- -56.62x
Enterprise value
- Enterprise value
- $7.3B
- EV / sales
- —
- EV / EBITDA
- -17.34x
- EV / EBIT
- -23.16x
- Market cap
- $7.8B
Trailing, forward and enterprise-value multiples for the requested listing · Data as of Jun 1, 2026